Under the terms of the agreement, pfizer will acquire all outstanding shares of metsera common stock for $47.50 per share in cash at closing, representing an enterprise value of approximately $4.9 billion. Pfizer has signed a deal to purchase metsera inc., an obesity drugmaker in the development stage, after winning a bidding war against novo nordisk. Why did pfizer win the metsera deal and what led novo nordisk to retreat after escalating its bid The agreement follows novo nordisk a/s (nyse Nvo) formally stepping away from its competing bid, citing regulatory challenges and.
WATCH
